Xeris Biopharma Holdings
XERS
110 hedge funds and large institutions have $102M invested in Xeris Biopharma Holdings in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 10 closing their positions.
1,210% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $132K
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
7% more funds holding
Funds holding: 103 → 110 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.88% less ownership
Funds ownership: 40.73% → 39.85% (-0.88%)
30% less capital invested
Capital invested by funds: $147M → $102M (-$44.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.5M |
| 2 |
Millennium Management
New York
|
+$1.06M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$951K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$893K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$797K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.09M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.01M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.99M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$574K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$497K |
XERS Hedge Fund Activity: Q3 2023 in Review
110 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2023, worth a combined $102M — down 30% from $147M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XERS positions and 10 closed out — a net gain of 7 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.5M. The largest seller was Invesco, cutting an estimated $4.09M.
- 110 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2023, up from 103 in Q2 2023.
- Funds reported $102M of Xeris Biopharma Holdings stock for Q3 2023, down 30% quarter-over-quarter.
- 17 funds opened new Xeris Biopharma Holdings positions in Q3 2023 and 10 closed out, a net change of +7 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2023 was Point72 Asset Management, an estimated $1.5M added.
- The largest Xeris Biopharma Holdings seller in Q3 2023 was Invesco, an estimated $4.09M sold.
Based on aggregated 13F filings for Q3 2023.